We are live on ! Find out more
STRO icon

Sutro Biopharma
STRO

120 hedge funds and large institutions have $252M invested in Sutro Biopharma in 2023 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 45 increasing their positions, 37 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

440% more call options, than puts

Call options by funds: $27K | Put options by funds: $5K

38% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 13

22% more repeat investments, than reductions

Existing positions increased: 45 | Existing positions reduced: 37

4% more funds holding

Funds holding: 115 → 120 (+5)

2% more capital invested

Capital invested by funds: $248M → $252M (+$4.09M)

0.35% less ownership

Funds ownership: 9.31% → 8.95% (-0.35%)

Holders
120
Holders Change
+5
Holders Change %
+4.35%
% of All Funds
1.88%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
18
Increased
45
Reduced
37
Closed
13
Calls
$27K
Puts
$5K
Net Calls
+$22K
Net Calls Change
+$25K

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$4.9M
2
Verition Fund Management
Verition Fund Management
Connecticut
+$3.99M
3
EP
Eversept Partners
New York
+$3.72M
4
Millennium Management
Millennium Management
New York
+$3.05M
5
KCM
Kynam Capital Management
New Jersey
+$2.98M

Top Sellers

Rank Fund Capital Flow
1
State Street
State Street
Massachusetts
-$9.1M
2
FLSM
Frazier Life Sciences Management
California
-$4.96M
3
Goldman Sachs
Goldman Sachs
New York
-$2M
4
AQR Capital Management
AQR Capital Management
Connecticut
-$1.55M
5
RCMNY
Rubric Capital Management (New York)
New York
-$1.55M
Name Holding Trade Value Shares
Change 		Change in
Stake
BlackRock
1
BlackRock
New York
$27.9M +$4.9M +98,474 +20%
SCM
2
Suvretta Capital Management
New York
$27.4M +$969K +19,460 +3%
RCMNY
3
Rubric Capital Management (New York)
New York
$18.8M -$1.55M -31,175 -7%
BI
4
BVF Inc
California
$15.6M – – –
Franklin Resources
5
Franklin Resources
California
$13.3M +$148K +2,967 +1%
Vanguard Group
6
Vanguard Group
Pennsylvania
$13.2M +$264K +5,295 +2%
Holocene Advisors
7
Holocene Advisors
New York
$9.92M – – –
Verition Fund Management
8
Verition Fund Management
Connecticut
$9.05M +$3.99M +80,087 +70%
Baillie Gifford & Co
9
Baillie Gifford & Co
United Kingdom
$8.68M – – –
SB
10
Samsara BioCapital
California
$7.79M – – –
CS
11
Candriam SCA
Luxembourg
$7.57M -$1.16M -23,255 -12%
Millennium Management
12
Millennium Management
New York
$6.99M +$3.05M +61,197 +69%
KCM
13
Kynam Capital Management
New Jersey
$6.97M +$2.98M +59,816 +66%
Dimensional Fund Advisors
14
Dimensional Fund Advisors
Texas
$5.63M +$192K +3,859 +3%
Geode Capital Management
15
Geode Capital Management
Massachusetts
$5.4M +$524K +10,522 +10%
PHP
16
Parkman Healthcare Partners
Connecticut
$5.32M +$218K +4,382 +4%
Goldman Sachs
17
Goldman Sachs
New York
$5.11M -$2M -40,174 -27%
State Street
18
State Street
Massachusetts
$5.09M -$9.1M -182,859 -63%
FLSM
19
Frazier Life Sciences Management
California
$3.63M -$4.96M -99,648 -56%
EP
20
Eversept Partners
New York
$3.48M +$3.72M +74,791 New
Acadian Asset Management
21
Acadian Asset Management
Massachusetts
$3.04M -$163K -3,277 -5%
Jacobs Levy Equity Management
22
Jacobs Levy Equity Management
New Jersey
$2.66M -$464K -9,321 -14%
Northern Trust
23
Northern Trust
Illinois
$2.25M +$140K +2,816 +6%
Vontobel Holding
24
Vontobel Holding
Switzerland
$1.93M +$2M +40,265 +3,097%
SAM
25
Sectoral Asset Management
Quebec, Canada
$1.86M +$1.99M +40,065 New
1
2 3 4 5

STRO Hedge Fund Activity: Q2 2023 in Review

120 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Sutro Biopharma (STRO) for Q2 2023, worth a combined $252M — up 1.7% from $248M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new STRO positions and 13 closed out — a net gain of 5 holders — while 45 added to existing stakes and 37 trimmed.

The largest buyer was BlackRock, adding an estimated $4.9M. The largest seller was State Street, cutting an estimated $9.1M.

  • 120 institutional investors held Sutro Biopharma (STRO) as of Q2 2023, up from 115 in Q1 2023.
  • Funds reported $252M of Sutro Biopharma stock for Q2 2023, up 1.7% quarter-over-quarter.
  • 18 funds opened new Sutro Biopharma positions in Q2 2023 and 13 closed out, a net change of +5 holders.
  • The largest Sutro Biopharma buyer in Q2 2023 was BlackRock, an estimated $4.9M added.
  • The largest Sutro Biopharma seller in Q2 2023 was State Street, an estimated $9.1M sold.

Based on aggregated 13F filings for Q2 2023.